The Conversation (0)
-
Melodiol Global Health Limited (ASX:ME1, FRA:1X8) (‘Melodiol’ or ‘the Company’), is delighted to announce a non-binding Letter of Intent (LOI) with the US-based entity, Panacea Life Sciences Holdings, Inc. (‘Panacea’) (OTCQB: PLSH). The LOI pertains to the divestment of two of Melodiol's prominent business units, Sierra Sage Herbs, LLC ("SSH") and Halucenex Life Sciences Inc. ("Halucenex"), for an up-front aggregate consideration of approximately U$5m in cash and scrip. The LOI also includes an additional US$15m in earn-out clauses, which if met, will provide additional value to Melodiol.
Highlights:
- Melodiol secures a non-binding LOI with Panacea Life Sciences Holdings, Inc. (‘Panacea’) (OTCQB: PLSH), a US company specialising in manufacturing, R&D, and distribution of high-quality, GMP-certified health & wellness products, for the sale of Sierra Sages Herbs, LLC (‘SSH’) and Halucenex Life Sciences Inc. (“Halucenex”) for an initial approximate US$5m in cash and scrip
- LOI includes additional earn-out components valued at up to US$15m, which will allow Melodiol to further increase its shareholding in Panacea should conditions be met following SSH’s potential revenue growth
- Panacea's recent operational progress includes acquisitions of eight retail locations offering VAPE and CBD products in Tampa, Florida, generating US$2.9m of annual revenues for the fiscal year ended 31 Dec 2022, and a research collaboration with Colorado State University’s Cannabinoid Research Centre (CRC)
- Panacea, through its diverse trademark portfolio (PANA Health, PANA Beauty, PANA Sport, PANA Pet, & PANA Life), operates across the entire cannabinoid value chain and achieved significant customer growth during Q1 CY2023
- Panacea is headquartered in Golden, Colorado where it operates a sophisticated 51,000 square foot, cGMP-certified facility
- Melodiol's divestment of SSH and Halucenex allows for concentration on group profitability, via the substantial growth at Health House International and Mernova Medicinal Inc., with the purchase price including US$2m in cash and the balance in Panacea common stock, promising further upside potential
- Post-transaction, Melodiol will be the largest shareholder in Panacea, enabling a strategic expansion into the US market. This aligns with the Company’s long stated objective to increase exposure to US capital markets
- Panacea's expertise will aid in the growth of SSH and Halucenex, significantly reducing Melodiol’s cash burn, and allowing ME1 to focus on accelerating the group’s near term profitability
- Transaction enables Panacea, a complementary US specialist business, to collaborate with SSH and Halucenex, driving growth and pursue cash flow positivity for SSH via potential synergies. Additionally, if completed, it would secure continued funding for Halucenex's progression into successful Phase II and forthcoming Phase III trials. This strategic move would also significantly decrease Melodiol's cash burn
- Consideration of A$30m highlights management’s view of Melodiol’s operating subsidiary value – further value accretive transactions for shareholders are also being explored
Panacea Life Sciences Holdings (https://panacealife.com/), is an OTCQB-listed holding company specialising in the development, manufacturing, research, and distribution of GMP-certified health & wellness and pet care products, chiefly those originating from hemp and CBD.
Panacea’s Extensive Product Suite
Its subsidiary, Panacea Life Sciences, Inc., driven by strong female leadership, prides itself on the research, production, and distribution of the highest-quality nutraceutical, cannabinoid, mushroom, kratom, and other natural, plant-based products. Panacea operates from a sophisticated 51,000 square foot, cGMP- certified facility in Golden, Colorado, ensuring unparalleled quality standards.
Click here for the full ASX Release
This article includes content from Melodial Global Health, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
Melodiol Global Health Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects
GET YOUR FREE INVESTOR KIT
Melodiol Global Health
Overview
The global regulatory climate around cannabis use is evolving and has resulted in a huge investment opportunity for investors seeking to capitalize on this emerging market. A significant player in the global cannabis market, Melodiol Global Health’s (ASX:ME1, FRA:1X8) value proposition is founded on its strategic operations in both Canada and Australia.
In recent years, countries like Canada and Australia have established new regulations to legalize cannabis use, either for recreational or medical purposes – or both. Other countries and regions are not far behind in their cannabis regulation journey.
Melodiol oversees multiple global business units that provide everything from recreational and medical cannabis to hemp-based, athletic, beauty and personal care products. Through subsidiary Halucenex Life Sciences, the company has also dipped its toes into the medical psychedelics market.
Melodiol's two most significant subsidiaries, by far, are Mernova and Health House International. The former is a licensed Canadian producer of small-batch, high-quality craft cannabis with incredibly strong revenue growth. The former is a leading distributor of medical cannabis in Australia with additional non-cannabis operations in the United Kingdom.
The company aims to increase shareholder value and spur further growth in its subsidiaries through optimisation which will ultimately result in improved operating and financial performance. Group revenues for the first half of 2023 totalled AU$6.99 million, representing a 62-percent increase from the same period in 2022 at AU$4.32 million.
Accounting for the recent acquisition of Health House International, unaudited pro forma revenue increased to AU$8.26 million or AU$33 million on an annualised basis — a 280-percent increase from the company's 2022 revenue. Unaudited net sales for the combined Melodiol group in Q2 2023 totaled $4.74 million, a 105-percent gain on the previous quarter and a 202-percent increase on the previous corresponding period. The company has also demonstrated a strong growth trajectory into Q3 2023.
Company Highlights
- A significant player in the global cannabis market, Melodiol Global Health is well-positioned to capitalise on a global trend toward recreational and medical cannabis legalization.
- Melodiol has built a diverse portfolio of plant-based brands situated in multiple high-growth market segments and geographies:
- Mernova, a licensed producer of craft cannabis products in Canada sold under the Ritual brand banner.
- Health House International is a leading Australian distributor of medicinal cannabis.
- Sierra Sage Herbs is an American developer of plant-based first aid, beauty and personal care brands Green Goo, Southern Butter and Good Goo.
- Creso ImpACTIVE, which produces high quality hemp-derived CBD products for athletes.
- Halucenex, a clinical-stage psychedelics research and development operation.
- Creso Pharma Switzerland, which carries out CBD-related research, development and commercialization initiatives.
- Melodiol has displayed incredibly strong financial performance throughout 2023, with significant revenue growth and notable improvements in core business unit EBITDA margins.
- The company intends to continue on its current path of generating value for shareholders through strong operational and financial performance.
Key Business Units
Mernova
Mernova product suite
Based in Canada, Mernova is a 100-percent-owned subsidiary of Melodiol. As a fully licensed cannabis producer, Mernova produces high-quality craft cannabis intended primarily for recreational use. Its products are among the most concentrated in the Canadian market, with THC content typically 25 percent or higher.
Mernova’s cannabis products are currently available in Saskatchewan, Ontario, Nova Scotia, New Brunswick, Manitoba, Yukon and Newfoundland. Mernova is notable as the first of Melodiol's divisions to generate positive cash flow from operations, achieving significant revenue growth in the first half of 2023. The company currently aims to bring its Mernova products to other markets within Canada and has recently launched a medicinal cannabis division.
Highlights:
- Purpose-built Facility: Mernova's 24,000-square-foot production facility fully adheres to Health Canada's GPP standards and is scalable up to 200,000 square feet.
- Branded Cannabis: Mernova markets its products under the Ritual brand, comprising three distinct segments:
- Ritual Green: Dried flower products
- Ritual Sticks: Pre-rolled joints
- Ritual Gold: Handheld vaporizers
- Revenue Growth: Mernova's total unaudited Q2 FY2023 sales totalled AU$1.22 million. This follows the company’s reported revenue increase of 46 percent from Q4 2022 to Q1 2023, hitting a record high of AU$1.55 million. This growth has had a significant positive impact on Melodiol's overall profits for the year.
Health House International
A leading distributor of medical cannabis products to the Australian market, Health House International also operates a division in the United Kingdom which distributes medicines and medicinal supplies. The business unit is primed to capitalise on any changes which might occur in the European regulatory climate. Melodiol acquired Health House International in the first quarter of 2023, resulting in a material increase in group revenues.
The company and its operating subsidiaries have delivered strong revenue and positive EBITDA margins throughout the first half of 2023. This trend is expected to continue for the remainder of the year.
Highlights:
- Recently Acquired: Melodiol's acquisition of Health House International closed in May 2023, cementing the company's leadership in the Australian cannabis market.
- Strong Growth Potential: The company generated AU$5.95 million in cash receipts in Q1 2023, a 10-percent increase on last quarter and a 36-percent increase over the previous corresponding period.
ImpACTIVE Limited
ImpACTIVE is a hemp-based athletics brand that provides CBD products to help athletes improve and redefine their recovery routines. In September 2023, the company secured a landmark sponsorship deal with Texas Christian University's highly reputed NCAA Division 1 sports program. The school's large athletics department boasts more than 200,000 social media followers alongside a large and loyal domestic fanbase.
Other ImpACTIVE brand ambassadors include Kevin Tansey, Mark Fraser, Matthew Barnaby, Nathaniel Behar, Colten Saucerman, Kelly Whaley, Will Wilcox and Troy Van Biezen.
Sierra Sage Herbs
Sierra Sage Herbs' primary offering is Green Goo, a branded line of plant-based first aid, beauty and personal care products. The company also maintains two other wholly owned brands, Southern Butter and Good Goo. In addition to a significant direct-to-consumer sales channel, Sierra Sage's distribution network includes key retail outlets across the United States, including Walmart, Walgreens, Target, Albertson and Whole Foods.
Halucenex Life Sciences
A clinical-stage psychedelic drug development company, Halucenex maintains a 6,000-square-foot Canadian medical facility with six treatment rooms and a secure laboratory dedicated to clinical research and psychedelics-assisted psychotherapy. The company has a Health Canada Controlled Drug and Substance Dealer's License for the possession, production, assembly, sale, provisioning, sending, transportation and delivery of multiple compounds including ketamine, psilocin, psilocybin and salvia divinorum.
Its phase 2 clinical trial test on the efficacy of psilocybin in the treatment of post-traumatic stress disorder (PTSD) has delivered promising results thus far, with the first 10 percent of trial patients experiencing total remission from both depression and PTSD symptoms after their first macro-dose.
Creso Pharma Switzerland
Creso Pharma Switzerland is a hemp-based food, feed supplements and topical products brand based in Europe. Backed by an experienced international team from the pharmaceutical industry, it serves the European Union, Switzerland, Eastern Europe, Latin America and Asia Pacific regions. The company's products are all Swiss-made, produced in GMP-certified facilities, as required, and made from EU-certified, GAP-compliant plants.
Management Team
William Lay — CEO and Managing Director
William Lay is a former investment banker who was involved in more than $5 billion worth of merger and acquisition deals in his role as an associate director at Canadian licenced producer Canopy Growth.
Boaz Wachtel — Chairman of the Board
A leading medical cannabis expert, Boaz Wachtel is co-founder and former MD of Phytotech Medical, Australia's first publicly-traded medicinal cannabis company.
Bruce Linton — Non-executive Director
Bruce Linton is the co-founder and former chairman of Canopy Growth, a world leader in cannabis and psychedelics.
Micheline MacKay — Executive Director
Micheline MacKay serves as managing director at Mernova, one of Melodiol's key business units. She has 22 years of experience in regulatory environments.
Ben Quirin — Non-executive Director
Based in Australia, Ben Quirin has over 20 years of experience in the global telecommunications, technology and pharmaceutical sectors. Prior to his role at Melodiol, Quirin served as regional managing director (APAC) for Canopy Growth.
Peter Hatfull — Non-executive Director
Peter Hatfull has over 40 years of experience in senior executive and board positions with various Australian and international companies.
Yuan (Tim) Tian — CFO
Tim Tian has more than 15 years of experience in financial controllership roles and has been Melodiol's financial controller over the last three years.
U.S. Cannabis Market Soars Amid Legal Reforms, But Safety Concerns Persist
FinancialBuzz.com News Commentary
The cannabis market in the United States has experienced significant growth in recent years, driven largely by an increasingly favorable legal environment. Since Colorado and Washington first legalized recreational marijuana in 2012, numerous states have followed suit, with 23 states and the District of Columbia now allowing adult-use cannabis as of 2023. This trend has fueled a burgeoning industry, with legal cannabis sales reaching $24 billion in 2021, a sharp increase from the $8.5 billion reported in 2017. Analysts project that the U.S. cannabis market could surpass $45 billion by 2025, supported by ongoing state-level legalizations and potential federal reforms. This rapid growth highlights the expanding acceptance of cannabis and its economic potential, with more states considering legalization to boost tax revenues and create jobs. Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO), Abbott Laboratories (NYSE: ABT), Tilray Brands, Inc. (NASDAQ: TLRY), Canopy Growth Corporation (NASDAQ: CGC), Cronos Group Inc. (NASDAQ: CRON)
Despite the market's promising outlook, concerns about cannabis use, particularly regarding public safety, persist. One significant issue is the impact of cannabis on driving abilities. Research indicates that marijuana can impair motor skills, reaction times, and judgment, raising the risk of traffic accidents. This concern underscores the importance of developing and deploying marijuana breathalyzers. These devices, similar to alcohol breathalyzers, detect the presence of tetrahydrocannabinol (THC), the psychoactive component in cannabis, by measuring the amount of THC in a user's breath. By providing law enforcement and employers with a tool to assess recent cannabis use accurately, these breathalyzers can help prevent accidents and encourage more responsible consumption. Ensuring that drivers are not under the influence of cannabis is critical for maintaining road safety and reducing the potential negative impacts associated with increased cannabis availability.
Cannabix Technologies Inc. (OTC: BLOZF) (CSE: BLO) just announced breaking news reports that, "early testing by Omega Laboratories Inc ("Omega Laboratories" or "Omega") with the Company's marijuana breathalyzer technology have garnered positive results. Omega has commenced pre-validation scoping work to establish limits of detection (LOD) and limits of quantification (LOQ) as well as the cutoff level for the detection of delta-9 THC (primary psychoactive ingredient in cannabis) in breath. Recently, Cannabix entered into a strategic partnership and development agreement with Omega Laboratories to advance the development and commercialization of the Cannabix marijuana breathalyzer technology. Omega Laboratories is an international industry leader in forensic drugs of abuse testing with multiple international certifications and accreditations.
Highlights:
- Omega scientists have established a delta-9 THC calibration curve with samples obtained from the Cannabix Breath Collection Unit (BCU) for the purposes of quantification using Omega's preexisting and well-established extraction and detection processes.
- Thus far, Omega scientists have been able to detect and quantify delta-9 THC in the low picogram range – a level of detection low enough for detecting drug compounds in breath.
- Omega scientists have consistently detected and quantified delta-9 THC from breath samples collected from subjects utilizing the Cannabix BCU.
- Omega scientists have developed a test method for a breath sample that successfully detects and differentiates between delta-9 THC, delta-8 THC, CBN and CBD. Cannabix and Omega have begun working together on multiple fronts including hardware refinement, marketing and preparing numerous validation studies.
Omega Laboratories is headquartered in Ohio, USA in a state-of-the-art facility providing drugs of abuse testing to over 6,000 clients worldwide, including several Fortune 500 companies, police, highway patrol, court systems, military organizations, and school systems. Omega also has one of the largest Third-Party Administrator (TPA) client lists in America.
Rav Mlait, CEO of Cannabix stated, "We are off to a terrific start alongside Omega Laboratories. We are working together to help provide a comprehensive marijuana breath testing solution for employers, law enforcement and others. Public policy in the United States towards cannabis is garnering additional attention as we move closer to the U.S. presidential election later this year where cannabis legalization could become a hot topic. Recently the DEA proposed rules to reclassify cannabis from a schedule I to a schedule III substance, further bolstering our expectation that the demand for marijuana drug testing will continue to increase."
About Omega Laboratories, Inc.
Omega Laboratories, headquartered in Mogadore, Ohio with additional state-of-the-art facilities in Ontario and British Columbia, Canada provides laboratory-based advanced testing solutions to over 6,000 clients worldwide. Omega Laboratories has over 24 years of experience in pioneering innovative drug testing methodologies, specializing in the detection of drugs of abuse utilizing Hair, Oral Fluid and Urine. Omega continues to innovate with the launch of their Technical Solutions portfolio that incorporates a paperless online Custody & Control Form system (oCCF) in eight languages, licensure of a Laboratory Information Management System (LIMS) designed specifically for Toxicology and powers new laboratories in countries that have demand for local service providers."
Abbott Laboratories (NYSE: ABT) unveiled its roadside drug-screening device, SoToxa™ Mobile Test System, back in 2019. SoToxa is a handheld device for law enforcement that uses an oral fluid swab – inserted into the handheld analyzer – that alerts police within five minutes whether a driver has recently used marijuana or other drugs. Because it collects only a small amount of oral fluid, the device is easier to administer than blood or urine tests, making it significantly easier for law enforcement to conduct the tests at the roadside, or in a police cruiser. SoToxa is able to test for the presence of THC (the psychoactive component in marijuana), cocaine, opioids, amphetamine, methamphetamine, and benzodiazepines.
Tilray Brands, Inc. (NASDAQ: TLRY) announced this week that its Good Supply cannabis brand has released its updated lineup of flavourful 1G 510 vapes with phenomenal potency featuring a wide selection of the best flavours to choose from for 710 and beyond. Good Supply is committed to promoting sustainability and an eco-conscious approach with its latest vape and product offerings. Emphasizing its "Green You Can Feel Good About" mantra, Good Supply's biodegradable vape mouthpieces and hemp tube containers not only provide reliable and potent products, but also have a positive impact on the planet. By mindfully composting them in organic processing or landfill facilities, you can confidently contribute to a greener planet.
Canopy Growth Corporation (NASDAQ: CGC) announced earlier this year the introduction of five new pre-roll products across the Company's adult-use cannabis portfolio from brands 7ACRES and Hiway. "Forging ahead with our commitment to innovation, we're excited to offer new pre-roll offerings that meet consumers across a range of occasions and price points," said Dave Paterson, President, Canada, Canopy Growth. "With convenience and enjoyment in mind, our new 7ACRES Smooth Burners offer a high-quality pre-roll with a unique filter design enabling a smooth and slow session, while our new Hiway Water Hash Infused pre-rolls provide consumers a premium experience in a value package."
Cronos Group Inc. (NASDAQ: CRON) reported last month that its Spinach® brand is expanding its portfolio of award-winning and best-selling cannabis products just in time for the summer months. Summer innovations feature new flavors and formats from Cronos' SOURZ by Spinach® edibles and a premier milled flower product. The new SOURZ by Spinach® Fully Blasted gummies offer the same great-tasting SOURZ by Spinach® flavors, now with 10 mg of THC per piece. The SOURZ by Spinach® Tropical Party Pack introduces new gummies with bolder tropical flavors, in the distinctive Spinach® "S" shape. These gummies have a perfect blend of sour and sweet and utilize Cronos' proprietary flavor-masking technology. Additionally, the Spinach® brand will introduce Spinach Grindz™, milled flower options designed to be ready to use for joints or vaporizers. Ready-to-use milled flower offerings have grown in popularity in the Canadian cannabis market, appealing to value-conscious consumers seeking convenience. Spinach Grindz™ caters to this growing demand by providing high-quality, milled cannabis that saves time and effort, allowing consumers to enjoy a consistent and hassle-free cannabis experience.
Subscribe Now! Watch us report LIVE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. FinancialBuzz.com has not been compensated directly by any of the companies mentioned here in this editorial unless mentioned otherwise. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For cannabix technologies inc. video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com
info@financialbuzz.com
+1-877-601-1879
www.FinancialBuzz.com
SOURCE FinancialBuzz.com
News Provided by GlobeNewswire via QuoteMedia
Trulieve Announces Opening of Affiliated Medical Marijuana Dispensary in Wilkes-Barre, Pennsylvania
New dispensary expands patient access to medical marijuana with ribbon cutting and pop-up event
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing marijuana company in the U.S., today announced the opening of a new Trulieve-affiliated medical marijuana dispensary in Wilkes-Barre, Pennsylvania .
The new affiliated dispensary, located at 1000 Wilkes Barre Township Boulevard, will host a grand opening celebration starting at 9 a.m. on Friday, July 12th , with a ribbon cutting, partner giveaways, special discounts and more.
"We are proud to expand access to medical marijuana in Pennsylvania with this new affiliated dispensary," said Trulieve's Chief Executive Officer Kim Rivers . "This location offers greater convenience to patients in Wilkes-Barre and Luzerne County looking for their favorite Trulieve branded products and our world-class customer service."
Additional Trulieve-affiliated dispensaries in Pennsylvania communities include Camp Hill , Coatesville , Cranberry Township , Devon , Harrisburg , Johnstown , King of Prussia , Limerick , Philadelphia , Philadelphia Charter City, Philadelphia Washington Square, Pittsburgh , Pittsburgh North Shore, Reading (on Lancaster ), Reading (on 5th St. Hwy), Scranton , Washington, Whitehall , York and Zelienople .
Trulieve Wilkes-Barre will be open 9 a.m. – 8 p.m. Monday through Saturday and 10 a.m. – 6 p.m. on Sundays . For more information, or to learn how to become a registered patient, visit Trulieve.com , follow us on Instagram at trulieve_pa or connect with Trulieve PA on Facebook.
About Trulieve
Trulieve is an industry leading, vertically integrated marijuana company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to marijuana, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-announces-opening-of-affiliated-medical-marijuana-dispensary-in-wilkes-barre-pennsylvania-302194155.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/11/c3662.html
News Provided by Canada Newswire via QuoteMedia
Trulieve to Open Medical Cannabis Dispensary in Gulf Breeze, Florida
New Santa Rosa County location will host grand opening celebration Friday, July 12th
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Gulf Breeze, Florida .
A grand opening celebration will be held Friday, July 12 th , beginning at 9 a.m. , featuring music, specials, discounts, and opportunities to register for upcoming patient education sessions as well as learn about #YesOn3 and the Florida ballot initiative for adult use.
"We are excited to bring Trulieve's world class customer service and assortment of high quality products to Gulf Breeze ," said Trulieve's Chief Executive Officer Kim Rivers . "We look forward to serving patients and caregivers in south Santa Rosa County ."
Trulieve Gulf Breeze, located at 3271 Gulf Breeze Pkwy, will be open 9 a.m. – 8:30 p.m. Monday through Saturday and 11 a.m. – 8 p.m. on Sundays , offering walk-in and express pickup service.
The new location will carry a wide variety of popular products including Trulieve's portfolio of in-house brands such as Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk, and Trekkers. Customers will also have access to beloved partner brands such as Alien Labs, Bellamy Brothers , Binske, Black Tuna, Blue River , Connected Cannabis, DeLisioso, Khalifa Kush , Love's Oven, Miami Mango, O.pen, Seed Junky, and Sunshine Cannabis, all available exclusively at Trulieve in Florida .
Across Florida , Trulieve offers home delivery, convenient online ordering, and in-store pickup. Veterans receive 20% off every order when they show their military ID, and all first-time guests are eligible for a 60% new customer discount at any Florida Trulieve location. For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook .
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-to-open-medical-cannabis-dispensary-in-gulf-breeze-florida-302192630.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/10/c8290.html
News Provided by Canada Newswire via QuoteMedia
Trulieve Cannabis Corp. to Hold Second Quarter 2024 Results Conference Call on August 6, 2024
Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., will hold a conference call on Tuesday, August 6, 2024 at 8:30 AM Eastern Time following the release of its second quarter 2024 financial results.
Chairman, Founder, and Chief Executive Officer Kim Rivers and Chief Financial Officer Wes Getman will participate on the call to review Trulieve's financial and operating results.
Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call and ask to join the Trulieve Cannabis Corp. call.
North American toll free: 1-844-824-3830 | Passcode: | 1732811 |
International: 1-412-542-4136 | Passcode: | 1732811 |
A live audio webcast of the conference call will be available at:
Trulieve Second Quarter 2024 Results Call
An archived replay of the webcast will be available at:
https://investors.trulieve.com/events
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .
Facebook: @Trulieve
Instagram: @Trulieve _
X: @Trulieve
Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-cannabis-corp-to-hold-second-quarter-2024-results-conference-call-on-august-6-2024-302191314.html
SOURCE Trulieve Cannabis Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/July2024/09/c4702.html
News Provided by Canada Newswire via QuoteMedia
Cronos Group Inc. to Reconvene Virtual 2024 Annual Meeting of Shareholders
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") announced today that it will reconvene its 2024 Annual Meeting of Shareholders on Friday, July 19, 2024, at 11:00 a.m. ET.
Cronos will be conducting the reconvened meeting in a virtual-only format via live audio webcast. Registered shareholders and duly appointed proxyholders will have an equal opportunity to participate in the reconvened 2024 Annual Meeting online regardless of their geographic location, including a chance to ask questions and vote.
The record date for the Annual Meeting continues to be April 25, 2024.
The Company's proxy statement and proxy supplement describing the formal business to be conducted at the meeting and containing detailed instructions about how to participate in the meeting are available on the Investors section of the Company's website at https://ir.thecronosgroup.com/financial-information/annual-meeting .
Access Information
Date: Friday, July 19, 2024
Time: 11:00 a.m. ET
Live Audio Webcast Online at: http://www.virtualshareholdermeeting.com/CRON2024
Replay
A replay of the reconvened Annual Meeting will be available in the investor relations section of the Company's website ( https://ir.thecronosgroup.com/events-presentations ) starting about 24 hours after the meeting is finished.
About Cronos
Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos' diverse international brand portfolio includes Spinach®, PEACE NATURALS® and Lord Jones®. For more information about Cronos and its brands, please visit: thecronosgroup.com .
Forward-looking Statements
This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos' intention to build an international iconic brand portfolio and develop disruptive intellectual property. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks. Financial results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, each of which has been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.
Cronos Group Contact
Shayne Laidlaw
Investor Relations
Tel: (416) 504-0004
investor.relations@thecronosgroup.com
News Provided by GlobeNewswire via QuoteMedia
Melodiol Global Health Investor Kit
- Corporate info
- Insights
- Growth strategies
- Upcoming projects